Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema

NCT02300701 is registered in ClinicalTrials.gov with Guy's and St Thomas' NHS Foundation Trust as lead sponsor.

NCT NCT02300701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02300701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema
Lead sponsor
Guy's and St Thomas' NHS Foundation Trust
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2014
Completion date
August 31, 2018
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, atopic eczema, child